As a scientist at argenx, Bram Van Den Eeckhout experiences the power of collaboration firsthand. In his role, he and his colleagues work alongside expert academic partners to develop new potential treatment candidates for autoimmune diseases. Partnerships with leaders in disease biology are made possible through our Immunology Innovation Program (IIP). Discover more about the program and our partners: https://bit.ly/4bH0EKL #TogetherWeDiscover
argenx
バイオテクノロジー研究
Boston、MA64,353人のフォロワー
United in our commitment to improve the lives of patients
概要
argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
- ウェブサイト
-
http://www.argenx.com
argenxの外部リンク
- 業種
- バイオテクノロジー研究
- 会社規模
- 社員 1,001 - 5,000名
- 本社
- Boston、MA
- 種類
- 上場企業
- 創立
- 2008
- 専門分野
- Oncology、Autoimmune diseases、Rare Diseases、Antibody based medicines、Immunotherapy、Myasthenia Gravis、Immunology、Pemphigus Vulgaris、Immune Thrombocytopenia、Acute Myeloid Leukemia 、high-risk myelodysplastic syndromes、chronic inflammatory demyelinating polyneuropathy
場所
argenxの社員
アップデート
-
We’re proud to celebrate our 10th Listing Anniversary with Euronext and the progress we’ve made over the past decade in translating immunology breakthroughs to innovative treatments. We remain committed to expanding our patient reach and advancing the rare disease treatment landscape. #TogetherWeDiscover
Today, we celebrated argenx's 10th listing anniversary. For the occasion, the three founders, Hans De Haard, Tim Van Hauwermeiren, and Torsten Dreier rang the market opening bell at our Brussels Euronext Office. argenx is a global immunology company developing novel antibody-based medicines for autoimmune diseases and cancer. They partner with academic researchers and advance multiple experimental medicines, with offices in Belgium, the United States, and Japan. The company is now revenue generating with its lead product. Since their listing in 2008, argenx has embarked on a remarkable journey, conquering new markets and continuously innovating. Today, I am proud to say that they are one of the most influential European biotech companies, being part of our BEL 20 and Euronext Tech Leaders indexes. I address my congratulations to argenx for their outstanding success and thanks all attendees of this bell ceremony. European Life Science Companies need significant amounts of financings. This can only happen with integrated capital markets. At Euronext we have made significant progress on this integration during the last decade with our seven listing venues, our four CSDs and our clearing house. Relentlessly, we must pursue the development the European capital markets union. We are on a mission ! #Euronext #Biotech #Innovation #argenX #EuronextTechLeaders #BEL20
-
-
Co-creation is paramount to our work. HCP Marketing Lead Jenny L. Reid and Clinical Scientist Stéphanie Dincq discuss how their teams prepared for our recent approval in #CIDP treatment, from designing the ADHERE trial, to connecting with patients and HCPs. #TogetherWeDiscover
-
At the European Academy of Neurology Congress, we're sharing how our collaborations with disease biology experts have helped us develop and deliver novel, targeted therapies for autoimmune patients in need. Learn more about our immunology research: https://bit.ly/3VPEhwu #TogetherWeDiscover #EAN2024
-
We are proud of our argonauts’ dedication to delivering innovative treatments to patients in need. Our recent FDA approval in chronic inflammatory demyelinating polyneuropathy (CIDP) is a testament to the value of collaborations with disease biology experts and the autoimmune patient community. Discover more about our work to advance #CIDP treatment: https://bit.ly/4cFeVZb #TogetherWeDiscover
-
At this year’s Peripheral Nerve Society Annual Meeting, we presented insights on the immune mechanisms in multifocal motor neuropathy (MMN). Learn more about our immunology research: bit.ly/3VJjs68 #TogetherWeDiscover #PNS2024
-
-
At argenx, we are committed to advancing the treatment landscape for rare, autoimmune diseases, like chronic inflammatory demyelinating polyneuropathy (CIDP). With our recent FDA approval, we are thrilled to provide the #CIDP community with a new, innovative treatment option. Learn more: bit.ly/4eIWlkT #TogetherWeDiscover
CIDP Treatment
-
For people living with autoimmune conditions, the disease burden remains high. We’re eager to share how our targeted solutions are addressing unmet autoimmune patient needs at the European Academy of Neurology Congress. Discover more about our commitment to this community: bit.ly/4eBL0Tu #TogetherWeDiscover #EAN2024
-
Today we announced the FDA approval of a new treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks a key advancement in the understanding of rare, autoimmune diseases, and we are proud to deliver a new, innovative option for the #CIDP community. #TogetherWeDiscover Learn more: https://bit.ly/45D76Rl
-
As a Clinical Scientist, Bianca Balbino (She/Her) collaborates with disease area experts to better understand treatment gaps and opportunities to bring innovative immunology solutions to patient communities. Discover opportunities to join argenx in transforming patient lives through innovation: https://bit.ly/3yXimM9 #TogetherWeDiscover #BiotechCareers
Your Future Fridays